Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Divestments (2021 - 2023)

Lifecore Biomedical, Inc. \De\ has reported Divestments over the past 3 years, most recently at -$15.7 million for Q2 2023.

  • Quarterly results put Divestments at -$15.7 million for Q2 2023, changed N/A from a year ago — trailing twelve months through Feb 2024 was -$15.7 million (down 200.0% YoY), and the annual figure for FY2022 was $45.1 million, changed.
  • Divestments for Q2 2023 was -$15.7 million at Lifecore Biomedical, Inc. \De\, down from $12.5 million in the prior quarter.
  • Over the last five years, Divestments for LFCR hit a ceiling of $45.1 million in Q3 2021 and a floor of -$15.7 million in Q2 2023.
  • Median Divestments over the past 3 years was $7.8 million (2022), compared with a mean of $11.3 million.
  • Peak annual rise in Divestments hit 93.05% in 2022, while the deepest fall reached 93.05% in 2022.
  • Lifecore Biomedical, Inc. \De\'s Divestments stood at $45.1 million in 2021, then tumbled by 93.05% to $3.1 million in 2022, then plummeted by 599.71% to -$15.7 million in 2023.
  • The last three reported values for Divestments were -$15.7 million (Q2 2023), $12.5 million (Q1 2023), and $3.1 million (Q3 2022) per Business Quant data.